source
- BioNTech's head and neck cancer mRNA vaccine fails to extend progression-free survival in Phase 3 trialBioNTech reported that its experimental mRNA immunotherapy BNT113 did not meet its primary endpoint in a Phase 3 trial for a specific head and neck cancer, failing to improve progression-free survi…
- Patient advocates and experts raise alarm over safety of Neurocrine Biosciences rare disease drugTwo months after an open letter highlighted possible safety issues, patient advocacy groups and several experts are publicly voicing growing alarm about a rare disease therapy marketed by Neurocrin…